201 related articles for article (PubMed ID: 28284351)
1. Is MuSK myasthenia gravis linked to IgG4-related disease?
Raibagkar P; Ferry JA; Stone JH
J Neuroimmunol; 2017 Apr; 305():82-83. PubMed ID: 28284351
[TBL] [Abstract][Full Text] [Related]
2. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
Front Immunol; 2020; 11():613. PubMed ID: 32431692
[TBL] [Abstract][Full Text] [Related]
3. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.
Koneczny I; Stevens JA; De Rosa A; Huda S; Huijbers MG; Saxena A; Maestri M; Lazaridis K; Zisimopoulou P; Tzartos S; Verschuuren J; van der Maarel SM; van Damme P; De Baets MH; Molenaar PC; Vincent A; Ricciardi R; Martinez-Martinez P; Losen M
J Autoimmun; 2017 Feb; 77():104-115. PubMed ID: 27965060
[TBL] [Abstract][Full Text] [Related]
4. Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies.
Verschuuren JJGM; Plomp JJ; Burden SJ; Zhang W; Fillié-Grijpma YE; Stienstra-van Es IE; Niks EH; Losen M; van der Maarel SM; Huijbers MG
Ann N Y Acad Sci; 2018 Feb; 1413(1):111-118. PubMed ID: 29356029
[TBL] [Abstract][Full Text] [Related]
5. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E
J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.
Plomp JJ; Huijbers MG; van der Maarel SM; Verschuuren JJ
Ann N Y Acad Sci; 2012 Dec; 1275():114-22. PubMed ID: 23278586
[TBL] [Abstract][Full Text] [Related]
7. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
Weger S; Appendino JP; Clark IH
J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
[TBL] [Abstract][Full Text] [Related]
8. Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG).
Çebi M; Durmuş H; Yılmaz V; Yentür SP; Aysal F; Oflazer P; Parman Y; Deymeer F; Saruhan-Direskeneli G
Clin Exp Immunol; 2019 Aug; 197(2):214-221. PubMed ID: 30929252
[TBL] [Abstract][Full Text] [Related]
9. Laboratory Investigation of Hybrid IgG4 k/λ in MuSK Positive Myasthenia Gravis.
Basile U; Napodano C; Gulli F; Pocino K; Di Santo R; Todi L; Basile V; Provenzano C; Ciasca G; Marino M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502051
[TBL] [Abstract][Full Text] [Related]
10. A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression.
Koneczny I; Mané-Damas M; Zong S; De Haas S; Huda S; van Kruining D; Damoiseaux J; De Rosa A; Maestri M; Guida M; Molenaar P; Van Damme P; Fichtenbaum A; Perkmann T; De Baets M; Lazaridis K; Zouvelou V; Tzartos S; Ricciardi R; Losen M; Martinez-Martinez P
Front Immunol; 2024; 15():1325171. PubMed ID: 38715598
[TBL] [Abstract][Full Text] [Related]
11. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1.
Niks EH; van Leeuwen Y; Leite MI; Dekker FW; Wintzen AR; Wirtz PW; Vincent A; van Tol MJ; Jol-van der Zijde CM; Verschuuren JJ
J Neuroimmunol; 2008 Mar; 195(1-2):151-6. PubMed ID: 18384886
[TBL] [Abstract][Full Text] [Related]
12. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice.
Klooster R; Plomp JJ; Huijbers MG; Niks EH; Straasheijm KR; Detmers FJ; Hermans PW; Sleijpen K; Verrips A; Losen M; Martinez-Martinez P; De Baets MH; van der Maarel SM; Verschuuren JJ
Brain; 2012 Apr; 135(Pt 4):1081-101. PubMed ID: 22396395
[TBL] [Abstract][Full Text] [Related]
13. IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.
Huijbers MG; Plomp JJ; van der Maarel SM; Verschuuren JJ
Ann N Y Acad Sci; 2018 Feb; 1413(1):92-103. PubMed ID: 29377160
[TBL] [Abstract][Full Text] [Related]
14. Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis.
Vergoossen DLE; Plomp JJ; Gstöttner C; Fillié-Grijpma YE; Augustinus R; Verpalen R; Wuhrer M; Parren PWHI; Dominguez-Vega E; van der Maarel SM; Verschuuren JJ; Huijbers MG
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753489
[TBL] [Abstract][Full Text] [Related]
15. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.
Huijbers MG; Zhang W; Klooster R; Niks EH; Friese MB; Straasheijm KR; Thijssen PE; Vrolijk H; Plomp JJ; Vogels P; Losen M; Van der Maarel SM; Burden SJ; Verschuuren JJ
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20783-8. PubMed ID: 24297891
[TBL] [Abstract][Full Text] [Related]
16. MuSK-Ab positive myasthenia: not always grave.
Zouvelou V; Stamboulis E; Skriapa L; Tzartos SJ
J Neurol Sci; 2013 Aug; 331(1-2):150-1. PubMed ID: 23706725
[TBL] [Abstract][Full Text] [Related]
17. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis.
Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C
Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611
[TBL] [Abstract][Full Text] [Related]
18. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
Zhou Y; Yan C; Gu X; Zhou L; Lu J; Zhu W; Huan X; Luo S; Zhong H; Lin J; Lu J; Zhao C; Xi J
Muscle Nerve; 2021 Jun; 63(6):824-830. PubMed ID: 33745138
[TBL] [Abstract][Full Text] [Related]
19. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.
Stein B; Bird SJ
J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497
[No Abstract] [Full Text] [Related]
[Next] [New Search]
